With Immunomedics ADC deal, Everest bolsters cancer pipeline

Undeterred by a complete response letter issued by FDA in January for Immunomedics' sacituzumab govitecan, Everest obtained the therapy's rights in several Asian territories, making the antibody-drug conjugate Everest's most advanced oncology asset thus far.

Everest Medicines Ltd. (Boston, Mass.) did adjust its offer following

Read the full 441 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE